Merck of Whitehouse Station, New Jersey, has halted development of its lead biogeneric product, MK-2578, a PEGylated erythropoietin-stimulating agent for treating anemia. The decision, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback